{"preliminary_commentary":{"by_channel":{"youtube":25,"podcast":22,"x_thread":8,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05514054\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"EMBER-4","nct_id":"NCT05514054","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ember-4-nct05514054. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EMBER-4","arms":[{"description":"Imlunestrant administered orally.","label":"Imlunestrant","type":"EXPERIMENTAL"},{"description":"Investigator's choice of tamoxifen, anastrozole, letrozole, or exemestane administered per local approved label.","label":"Investigator's Choice of Endocrine Therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-03","type":"ESTIMATED"},"conditions":["Breast Neoplasms"],"enrollment":{"count":8000,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Imlunestrant","otherNames":["LY3484356"],"type":"DRUG"},{"name":"Tamoxifen","otherNames":[],"type":"DRUG"},{"name":"Anastrozole","otherNames":[],"type":"DRUG"},{"name":"Letrozole","otherNames":[],"type":"DRUG"},{"name":"Exemestane","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-02","lead_sponsor":"Eli Lilly and Company","official_title":"EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Invasive Disease-Free Survival (IDFS)","timeFrame":"Randomization to recurrence or death from any cause (up to 10 years)"}],"references":[],"start_date":{"date":"2022-10-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05514054"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ember-4-nct05514054"}